Cargando…

Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial

BACKGROUND: Women with pathogenic BRCA1 or BRCA2 variants are at high risk for breast and ovarian cancer. Preventive options include risk-reducing breast and ovarian surgeries and intensified breast surveillance. However, individual decision-making is often associated with decisional conflicts. Two...

Descripción completa

Detalles Bibliográficos
Autores principales: Kautz-Freimuth, Sibylle, Redaèlli, Marcus, Shukri, Arim, Kentenich, Hannah, Simic, Dusan, Mildenberger, Vanessa, Schmutzler, Rita, Rhiem, Kerstin, Stock, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580583/
https://www.ncbi.nlm.nih.gov/pubmed/37845719
http://dx.doi.org/10.1186/s12911-023-02327-9
_version_ 1785121972710014976
author Kautz-Freimuth, Sibylle
Redaèlli, Marcus
Shukri, Arim
Kentenich, Hannah
Simic, Dusan
Mildenberger, Vanessa
Schmutzler, Rita
Rhiem, Kerstin
Stock, Stephanie
author_facet Kautz-Freimuth, Sibylle
Redaèlli, Marcus
Shukri, Arim
Kentenich, Hannah
Simic, Dusan
Mildenberger, Vanessa
Schmutzler, Rita
Rhiem, Kerstin
Stock, Stephanie
author_sort Kautz-Freimuth, Sibylle
collection PubMed
description BACKGROUND: Women with pathogenic BRCA1 or BRCA2 variants are at high risk for breast and ovarian cancer. Preventive options include risk-reducing breast and ovarian surgeries and intensified breast surveillance. However, individual decision-making is often associated with decisional conflicts. Two evidence-based decision aids have recently been developed for these women (healthy or with unilateral breast cancer) for the German context to support them in their decision-making process. This study evaluated their effectiveness. METHODS: In a randomized controlled study, women (aged 18–70 years) with pathogenic BRCA1 or BRCA2 variants were randomly assigned 1:1 to the intervention (IG, n = 230) or control (CG, n = 220) group. All participants received usual care. After baseline survey (t0), IG participants additionally received the DAs. Follow-up surveys were at three (t1) and six (t2) months. Primary outcome was decisional conflict at t1. Secondary analyses included decision status, decision regret, knowledge on risks and preventive options, self-reported psychological symptoms, acceptability of DAs, and preparation for decision-making. RESULTS: Of 450 women recruited, 417 completed t0, 398 completed t1 and 386 completed t2. Compared to CG, IG participants had lower decisional conflict scores at t1 (p = 0.049) and t2 (p = 0.006) and higher scores for knowledge (p = 0.004), acceptability (p = 0.000), and preparation for decision-making (p < 0.01). CONCLUSIONS: These DAs can help improve key parameters of decision-making in women with pathogenic BRCA1 and BRCA2 variants and, thus, provide a useful add-on to the current counseling and care concept for these women in Germany. TRIAL REGISTRATION: German Clinical Trials Register, DRKS-ID: DRKS00015823, retrospectively registered 14/06/2019.
format Online
Article
Text
id pubmed-10580583
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105805832023-10-18 Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial Kautz-Freimuth, Sibylle Redaèlli, Marcus Shukri, Arim Kentenich, Hannah Simic, Dusan Mildenberger, Vanessa Schmutzler, Rita Rhiem, Kerstin Stock, Stephanie BMC Med Inform Decis Mak Research BACKGROUND: Women with pathogenic BRCA1 or BRCA2 variants are at high risk for breast and ovarian cancer. Preventive options include risk-reducing breast and ovarian surgeries and intensified breast surveillance. However, individual decision-making is often associated with decisional conflicts. Two evidence-based decision aids have recently been developed for these women (healthy or with unilateral breast cancer) for the German context to support them in their decision-making process. This study evaluated their effectiveness. METHODS: In a randomized controlled study, women (aged 18–70 years) with pathogenic BRCA1 or BRCA2 variants were randomly assigned 1:1 to the intervention (IG, n = 230) or control (CG, n = 220) group. All participants received usual care. After baseline survey (t0), IG participants additionally received the DAs. Follow-up surveys were at three (t1) and six (t2) months. Primary outcome was decisional conflict at t1. Secondary analyses included decision status, decision regret, knowledge on risks and preventive options, self-reported psychological symptoms, acceptability of DAs, and preparation for decision-making. RESULTS: Of 450 women recruited, 417 completed t0, 398 completed t1 and 386 completed t2. Compared to CG, IG participants had lower decisional conflict scores at t1 (p = 0.049) and t2 (p = 0.006) and higher scores for knowledge (p = 0.004), acceptability (p = 0.000), and preparation for decision-making (p < 0.01). CONCLUSIONS: These DAs can help improve key parameters of decision-making in women with pathogenic BRCA1 and BRCA2 variants and, thus, provide a useful add-on to the current counseling and care concept for these women in Germany. TRIAL REGISTRATION: German Clinical Trials Register, DRKS-ID: DRKS00015823, retrospectively registered 14/06/2019. BioMed Central 2023-10-16 /pmc/articles/PMC10580583/ /pubmed/37845719 http://dx.doi.org/10.1186/s12911-023-02327-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kautz-Freimuth, Sibylle
Redaèlli, Marcus
Shukri, Arim
Kentenich, Hannah
Simic, Dusan
Mildenberger, Vanessa
Schmutzler, Rita
Rhiem, Kerstin
Stock, Stephanie
Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial
title Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial
title_full Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial
title_fullStr Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial
title_full_unstemmed Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial
title_short Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial
title_sort effectiveness of evidence-based decision aids for women with pathogenic brca1 or brca2 variants in the german health care context: results from a randomized controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580583/
https://www.ncbi.nlm.nih.gov/pubmed/37845719
http://dx.doi.org/10.1186/s12911-023-02327-9
work_keys_str_mv AT kautzfreimuthsibylle effectivenessofevidencebaseddecisionaidsforwomenwithpathogenicbrca1orbrca2variantsinthegermanhealthcarecontextresultsfromarandomizedcontrolledtrial
AT redaellimarcus effectivenessofevidencebaseddecisionaidsforwomenwithpathogenicbrca1orbrca2variantsinthegermanhealthcarecontextresultsfromarandomizedcontrolledtrial
AT shukriarim effectivenessofevidencebaseddecisionaidsforwomenwithpathogenicbrca1orbrca2variantsinthegermanhealthcarecontextresultsfromarandomizedcontrolledtrial
AT kentenichhannah effectivenessofevidencebaseddecisionaidsforwomenwithpathogenicbrca1orbrca2variantsinthegermanhealthcarecontextresultsfromarandomizedcontrolledtrial
AT simicdusan effectivenessofevidencebaseddecisionaidsforwomenwithpathogenicbrca1orbrca2variantsinthegermanhealthcarecontextresultsfromarandomizedcontrolledtrial
AT mildenbergervanessa effectivenessofevidencebaseddecisionaidsforwomenwithpathogenicbrca1orbrca2variantsinthegermanhealthcarecontextresultsfromarandomizedcontrolledtrial
AT schmutzlerrita effectivenessofevidencebaseddecisionaidsforwomenwithpathogenicbrca1orbrca2variantsinthegermanhealthcarecontextresultsfromarandomizedcontrolledtrial
AT rhiemkerstin effectivenessofevidencebaseddecisionaidsforwomenwithpathogenicbrca1orbrca2variantsinthegermanhealthcarecontextresultsfromarandomizedcontrolledtrial
AT stockstephanie effectivenessofevidencebaseddecisionaidsforwomenwithpathogenicbrca1orbrca2variantsinthegermanhealthcarecontextresultsfromarandomizedcontrolledtrial